Induction therapy + Corticosteroids + EVR+rCNI + MPA+sCNI
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
End Stage Renal Disease (ESRD)
Conditions
End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis, Renal Replacement Therapy, Renal Transplantation
Trial Timeline
Dec 3, 2013 → Jan 17, 2018
NCT ID
NCT01950819About Induction therapy + Corticosteroids + EVR+rCNI + MPA+sCNI
Induction therapy + Corticosteroids + EVR+rCNI + MPA+sCNI is a approved stage product being developed by Novartis for End Stage Renal Disease (ESRD). The current trial status is completed. This product is registered under clinical trial identifier NCT01950819. Target conditions include End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01950819 | Approved | Completed |
Competing Products
20 competing products in End Stage Renal Disease (ESRD)